Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Hims & Hers (HIMS) is expanding its playbook across the Atlantic — the U.S.-based telehealth company announced Tuesday that ...

FRANKFURT, Germany — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk stock (NVO) jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first quarter and despite a slight cut to its sales forecast for the year.

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...